Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,121 | 411 | 1,665 |
| Samples | 1,431 | 310 | 1,089 |
| Peptides | 1,529 | 258 | 1,276 |
Function
AKAP9 · A-kinase anchoring protein 9
The A-kinase anchor proteins (AKAPs) are a group of structurally diverse proteins which have the common function of binding to the regulatory subunit of protein kinase A (PKA) and confining the holoenzyme to discrete locations within the cell. This gene encodes a member of the AKAP family. Alternate splicing of this gene results in at least two isoforms that localize to the centrosome and the Golgi apparatus, and interact with numerous signaling proteins from multiple signal transduction pathways. These signaling proteins include type II protein kinase A, serine/threonine kinase protein kinase N, protein phosphatase 1, protein phosphatase 2a, protein kinase C-epsilon and phosphodiesterase 4D3. [provided by RefSeq, Aug 2008].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000356239 | Q99996 | 1,887 | 1,367 |
| ENST00000359028 | A0A0A0MRF6* | 150 | 121 |
| ENST00000680766 | Q99996-3 | 77 | 59 |
| ENST00000680534 | A0A7P0TBI4* | 6 | 5 |
| ENST00000680513 | A0A7P0T8N5* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 1367 amino-acid changes on canonical ENST00000356239 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in AKAP9 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in AKAP9 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Gastrointestinal Stromal Tumour | 0/0 0% | 21/133 16% |
| T-Cell Non-Hodgkins Lymphoma | 4/26 15% | 0/0 0% |
| Endometrial Carcinoma | 15/42 36% | 60/612 10% |
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Melanoma | 19/210 9% | 125/1899 7% |
| Bladder Carcinoma | 3/58 5% | 64/956 7% |
| Non-Small Cell Lung Carcinoma | 38/304 12% | 65/1390 5% |
| Acute Myeloid Leukemia | 5/90 6% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 12/57 21% | 34/810 4% |
| Colorectal Carcinoma | 35/143 24% | 141/3239 4% |
| Gastric Carcinoma | 16/74 22% | 81/1809 4% |
| Glioblastoma | 5/98 5% | 0/0 0% |
| Neuroendocrine Tumour | 15/154 10% | 14/577 2% |
| Hodgkins Lymphoma | 2/16 12% | 3/122 2% |
| Other Solid Cancers | 10/94 11% | 47/1515 3% |
| Cervical Carcinoma | 3/35 9% | 11/422 3% |
| Ovarian Carcinoma | 15/109 14% | 17/998 2% |
| Esophageal Carcinoma | 0/23 0% | 21/769 3% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 64/2550 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Unknown | 0/10 0% | 1/29 3% |
| Ewings Sarcoma | 5/63 8% | 3/262 1% |
| Head and Neck Carcinoma | 2/85 2% | 37/1574 2% |
| Plasma Cell Myeloma | 5/44 11% | 3/305 1% |
| Hepatocellular Carcinoma | 5/46 11% | 46/2210 2% |
| Kidney Carcinoma | 12/85 14% | 32/1862 2% |
| Chondrosarcoma | 1/14 7% | 1/75 1% |
| Other Sarcomas | 6/69 9% | 10/699 1% |
| Biliary Tract Carcinoma | 0/54 0% | 20/950 2% |
| Small Cell Lung Carcinoma | 2/9 22% | 13/752 2% |
Mutation Distribution
Where AKAP9 is mutated · all tissues, split by cell line vs tissue
How many mutations in AKAP9 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,121 mutations in AKAP9
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|